Newark, CA, United States of America

Deepali Sawant

USPTO Granted Patents = 1 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Deepali Sawant: Innovator in Cancer Treatment

Introduction

Deepali Sawant is a prominent inventor based in Newark, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic antibodies. Her work focuses on targeting specific pathways to enhance treatment efficacy while minimizing side effects.

Latest Patents

Deepali Sawant holds a patent for her invention titled "Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors." This groundbreaking invention relates to a human agonistic CD40 multispecific antibody construct designed for the treatment of solid tumors. It specifically targets the CD40 pathway on tumor-associated antigen-presenting cells (APCs) without causing systemic CD40 activation. This innovative approach aims to improve therapeutic outcomes for patients suffering from solid tumors.

Career Highlights

Deepali is currently employed at Amgen Inc., a leading biotechnology company known for its focus on innovative therapies. Her work at Amgen has allowed her to collaborate with some of the brightest minds in the industry, further advancing her research and contributions to cancer treatment.

Collaborations

Some of her notable coworkers include Xin Yu and Jackson Egen, who have worked alongside her in various projects aimed at developing effective cancer therapies.

Conclusion

Deepali Sawant's contributions to the field of cancer treatment through her innovative patent and work at Amgen Inc. highlight her dedication to improving patient outcomes. Her research continues to pave the way for advancements in therapeutic strategies against solid tumors.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…